Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial
Conclusion: In the MIYABI ND-C study, molidustat appeared to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.Am J Nephrol
Source: American Journal of Nephrology - Category: Neurology Source Type: research
More News: Anemia | Aranesp | Chronic Kidney Disease | Clinical Trials | Dialysis | Japan Health | Neurology | Study | Urology & Nephrology